Novel antiviral agent based on modified chitosan

テクノロジー The subject of this licensing opportunity is the use of modified natural polysaccharides for the treatment and prevention of viral infections caused by the coronaviruses. The invention may be particularly useful for controlling potentially deadly SARS infections.